Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A2-73 is more than a sigma-1 agonist. There is a wealth of study around this that provides more information, but don't short the complexity of this compound and what it has to offer. Look at the whole picture.
Maybe this assumption and conclusion...
Large deposits of amyloid beta are believed to cause neurological destruction that results in AD. Amyloid beta formed in the brain’s axons and nerve endings causes the worst damage in AD by impairing communication between nerve cells (or neurons) in the brain. Researchers around the world have worked intensely to find ways to block the formation of amyloid beta by preventing cleavage by beta secretase and gamma secretase. However, these approaches have been hampered by safety issues.
Truth is if 273 pans out as a global CNS treatment, we'll be right there with the big boys in terms of market cap
Define ethical.
That was not the end game for Anavex or me as an investor, and it would be wrong to price in all the other operations into rett alone. If this company is only successful in the rett indication, they should simply cut thier losses and license to a larger company that can absorb all the overhead, not paying millions to the CEO and Accountant for one small indication alone.
Anavex should price according to projected future success in at least one other indication. Revenue now helps fund future operation, but should not support all operations. Don't punish rett patients because we invested in something bigger.
Thanks, George.
NIH funding... How would you compare these results? Did SAVA use any biomarkers or any unusual exclusions or is the 50 patient population random and wild?
Those results look impressive.
What do you think about those results George? It seems like SAVA has alot more momentum and alot less baggage.
Chris was not the original patent holder, nor was Anavex, of either compound.
Half a billion, not bad for a $1.5 billion company... maybe I should have sold all my shares with Sandra and Chris.
There are several coincidental timing issues.
$7-$14?
Government healthcare?
Never understood this argument. Let's have a bunch of preffered shares to deter a potential acquirer. That also makes the stock unattractive to potential investors.
$12 looks like a strong support level.
Nice assumption. Maybe another trial. Seems people always take things from one extreme to the other. Another trial would be a waste if the sample population is diverse and there is a significant correlation to dosing. It is sad that social influences have such a strong impact without basis other than feelings. I hope the TGA approves if this is the case.
Take it that you invested in PRAN too.
Yeah, your right, tax deferred.
Maybe this week. Hope your right this time. A short squeeze would be nice.
Yeah, everyone would want to take it all the time!
Did Dr. Tanzi ever complete the petri dish alzheimers model? Seemed like a cool idea. Makes me wonder about the influence of other systems in the body though.
I believe you only pay taxes on profit, not cost basis.
Let's see how that plays out...
Hmm, do you think someone telegraphed the news? Same old, same old. Why raise capital when you know you have another announcement to make? The answer is not the cabal.
More dillution.
Must be TGD.
SAVA MC $3.27B AVXL MC $1.94B
It's the same old BS with this stock.
Stocks usually go up on good news...
Every time!
Great data with huge market, and only $2.17 Billion market cap.
This should be well over $50!
I would like to be wrong. In my uneducated perspective the charts indicate that unless we get some type of news early next week the share price will decline. Not to say someone could start buying, but it appears interest is starting to wane again.
Right now it is looking like next week.
Is there something pending?
It's sad; a sanctioned scam that preys on the weak and desperate.
$2 Billion? So treatment for those 50,000,000 people is going to only cost $50 annually. Pretty sure they missed at least one zero. Thinking should be $2 Trillion.
Well it would certainly impact negotiations if there were any with Anavex. These approvals are disappointing.
Hmm, competition gets breakthrough MC falls. Market share lowered? How does that impact calculations for AVXL market share?